Autori: Weichenthal Michael
| Naslov | BRAF/MEK inhibitor rechallenge in patients with non-resectable or metastatic BRAF V600-mutated melanoma: A stratified, controlled, retrospective EUMelaReg multicenter study (Article) |
| Autori | Weichenthal Michael ... Popovic Aleksandar ... (broj koautora 31) |
| Info | EJC SKIN CANCER, (2026), vol. 4 br. , str. - |
| Projekat | Novartis AG, Basel, Switzerland |
| Ispravka | ISI/Web of Science Članak Elečas |
| Naslov | Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe (Article) |
| Autori | Weichenthal Michael ... Kandolf Lidija O ... (broj koautora 22) |
| Info | CANCERS, (2024), vol. 16 br. 21, str. - |
| Projekat | Merck Sharp Dohme LLC; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa |
